Cargando…
MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
BACKGROUND: In the absence of targetable mutations or immune checkpoints, cisplatin-doublet chemotherapy remains the standard of care in non-small cell lung cancer (NSCLC). Drug resistance has however become a significant clinical challenge. Exploring a role for small non-coding microRNAs (miRNA) as...
Autores principales: | MacDonagh, Lauren, Gallagher, Michael F., Ffrench, Brendan, Gasch, Claudia, Gray, Steven G., Reidy, Marie, Nicholson, Siobhan, Leonard, Niamh, Ryan, Ronan, Young, Vincent, O’Leary, John J., Cuffe, Sinead, Finn, Stephen P., O’Byrne, Kenneth J., Barr, Martin P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107736/ https://www.ncbi.nlm.nih.gov/pubmed/34012792 http://dx.doi.org/10.21037/tlcr-20-959 |
Ejemplares similares
-
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
por: MacDonagh, Lauren, et al.
Publicado: (2017) -
Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin
por: MacDonagh, Lauren, et al.
Publicado: (2021) -
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016) -
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention
por: Ffrench, Brendan, et al.
Publicado: (2014) -
Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention
por: Gasch, Claudia, et al.
Publicado: (2017)